Back to News
Market Impact: 0.32
ANI Pharmaceuticals Wins FDA Approval For Generic Everolimus Tablets For Oral Suspension
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
ANI Pharmaceuticals received FDA approval for its abbreviated new drug application for Everolimus Tablets for Oral Suspension in 2mg, 3mg, and 5mg strengths. The product is a generic version of Novartis's Afinitor Disperz, expanding ANI's generic pharmaceutical portfolio and enabling a potential commercial launch.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
ANIP0.70
More News
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Meta announces new lightweight virtual reality glasses to one-up Apple’s Vision Pro
- How Meta took the lead in the race for the post-smartphone world
- Oil industry warns a diesel export ban will raise fuel prices as Trump weighs restrictions
- Australia says OpenAI agent hacked Medicare portal
- Mark Zuckerberg debuts $1,299 Meta VR Glasses and Muse Charm pendant amid AI agent push